PARP inhibitor Archives -

Disappointment as Lynparza fails colorectal cancer test

Phil Taylor AstraZeneca, colorectal cancer, Lynparza, Merck & Co, Oncology, PARP inhibitor 0 Comment

AstraZeneca and Merck’s PARP inhibitor Lynparza has carved out blockbuster revenues across uses in breast, ovarian, prostate and

Disappointment as Lynparza fails colorectal cancer test

https://pharmaphorum.com/news/disappointment-as-lynparza-fails-colorectal-cancer-test/

News/ News/ Oncology

AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy

Phil Taylor AstraZeneca, BRCA, breast cancer, Merck & Co, Oncology, PARP inhibitor, regulatory approval, targeted oncology 0 Comment

The FDA has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast

AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy

https://pharmaphorum.com/news/az-merck-get-fda-okay-for-lynparza-as-adjuvant-breast-cancer-therapy/

Market Access/ News/ News

After a Scottish aye, NICE says no to Lynparza for prostate cancer

Phil Taylor AstraZeneca, HEOR, Lynparza, NICE, PARP inhibitor, Prostate cancer 0 Comment

AstraZeneca’s PARP inhibitor Lynparza should not be made available routinely on the NHS n England and Wales as

After a Scottish aye, NICE says no to Lynparza for prostate cancer

https://pharmaphorum.com/news/after-a-scottish-aye-nice-says-no-to-lynparza-for-prostate-cancer/

News/ News/ Oncology

PROpel study backs Lynparza combo in first-line prostate cancer

Phil Taylor AstraZeneca, Lynparza, Merck & Co, Oncology, PARP inhibitor, Prostate cancer 0 Comment

AstraZeneca and Merck & Co PARP inhibitor Lynparza is already used to treat prostate cancer associated with a

PROpel study backs Lynparza combo in first-line prostate cancer

https://pharmaphorum.com/news/propel-study-backs-lynparza-combo-in-first-line-prostate-cancer/

News/ News/ Oncology

ASCO21: Lynparza aces adjuvant breast cancer therapy trial

Phil Taylor adjuvant, ASCO 2021, AstraZeneca, breast cancer, Lynparza, Merck & Co, Oncology, PARP inhibitor 0 Comment

AstraZeneca and Merck & Co’s Lynparza is primed for even wider use in the treatment of breast cancer

ASCO21: Lynparza aces adjuvant breast cancer therapy trial

https://pharmaphorum.com/news/asco21-lynparza-aces-adjuvant-breast-cancer-therapy-trial/

Market Access/ News/ News

NICE says no to AZ’s Lynparza for prostate cancer

Phil Taylor AstraZeneca, HEOR, Lynparza, NHS, NICE, Oncology, PARP inhibitor, Prostate cancer, UK 0 Comment

NHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they

NICE says no to AZ’s Lynparza for prostate cancer

https://pharmaphorum.com/news/nice-says-no-to-azs-lynparza-for-prostate-cancer/

News/ News/ Oncology

Filing beckons as Lynparza hits the mark in adjuvant breast cancer

Phil Taylor adjuvant, AstraZeneca, breast cancer, Lynparza, Oncology, PARP inhibitor 0 Comment

AstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer,

Filing beckons as Lynparza hits the mark in adjuvant breast cancer

https://pharmaphorum.com/news/filing-beckons-as-lynparza-hits-the-mark-in-adjuvant-breast-cancer/

Digital/ Events/ Events

Triple Negative Breast Cancer Drug Development Digital Summit

jenna.warren@hansonwade.com adc, immunotherapy, Oncology, PARP inhibitor, TNBC 0 Comment

Fast-track the Discovery & Development of TNBC

Triple Negative Breast Cancer Drug Development Digital Summit

https://pharmaphorum.com/events/triple-negative-breast-cancer-drug-development-digital-summit/

News/ News/ Oncology

AZ, Merck add pancreatic cancer to Lynparza’s growing use list

Phil Taylor AstraZeneca, Lynparza, Merck & Co, pancreatic cancer, PARP inhibitor 0 Comment

AstraZeneca and Merck & Co have cemented their lead in the PARP inhibitor class with FDA approval for

AZ, Merck add pancreatic cancer to Lynparza’s growing use list

https://pharmaphorum.com/news/az-merck-add-pancreatic-cancer-to-lynparzas-growing-use-list/

Trending

PARP inhibitor

Login